Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Peter D.R Higgins
Doubling the Infliximab Dose Versus Halving the Infusion Intervals in Crohnʼs Disease Patients With Loss of Response
Inflammatory Bowel Diseases
Allergy
Immunology
Gastroenterology
Related publications
Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?
Digestive Diseases and Sciences
Physiology
Gastroenterology
Mechanisms That Mediate the Development of Fibrosis in Patients With Crohnʼs Disease
Inflammatory Bowel Diseases
Allergy
Immunology
Gastroenterology
Low-Dose Glucocorticoid Therapy Decreases Risk for Treatment-Limiting Infusion Reaction to Infliximab in Patients With Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Neuropathy in Parkinson’s Disease Patients With Intestinal Levodopa Infusion Versus Oral Drugs
PLoS ONE
Multidisciplinary
Increase in Methotrexate Dose in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Infliximab
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease
The Lancet
Medicine
Cisatracurium Dose–response Relationship in Patients With Chronic Liver Disease
Egyptian Journal of Anaesthesia
Anesthesiology
Pain Medicine
Risk Factors for Metabolic Bone Disease in Crohnʼs Disease Patients
Inflammatory Bowel Diseases
Allergy
Immunology
Gastroenterology
